Lupin surges on receiving Health Canada's approval for Rymti
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Lupin is currently trading at Rs. 673.50, up by 1.95 points or 0.29% from its previous closing of Rs. 671.55 on the BSE.
The scrip opened at Rs. 670.15 and has touched a high and low of Rs. 674.80 and Rs. 668.85 respectively. So far 15212 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 995.00 on 15-Sep-2021 and a 52 week low of Rs. 583.05 on 25-May-2022.
Last one week high and low of the scrip stood at Rs. 674.80 and Rs. 647.05 respectively. The current market cap of the company is Rs. 30640.23 crore.
The promoters holding in the company stood at 47.10%, while Institutions and Non-Institutions held 41.45% and 11.45% respectively.
Lupin has received Health Canada approval for Rymti, its biosimilar to Enbrel (etanercept), for use in Canada. Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis. The company is committed to enhancing patient access to high-quality, life-enhancing biosimilars.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
